Huiyu Pharmaceutical's 3 major injections led the list of 4 and 7 varieties sales surged 325 times

Shoulder Hengrui, Zhongsheng, 3 varieties leading injection over-rated listfigure: over-rated injection varieties of 2 or more enterprises (in group)meters of intranet data show that there are currently 46 acceptance numbers for injections approved or as a matter of conformity evaluation (in terms of drug names) A total of 30 varieties), involving 26 enterprises (in group terms), of which 6 enterprises have rated the number of injection varieties up to 2 or more, Huiyu Pharmaceuticals, Hengrui Pharmaceuticals, China Biopharmaceuticals with 3 over-rated varieties and ranked first, involving the number of 7, 3, 3Table 1: Huiyu Pharmaceutical has been evaluated varieties
Huiyu Pharmaceuticalhas has been evaluated 3 injections are anti-tumor drugs, Minet data show that in 2018 China's urban public hospitals, county-level public hospitals, urban community centers and township health hospitals (referred to as China's public medical institutions) terminal anti-tumor drug products competition pattern, injection with Pemequce disodium, dositasai injections with 6.77%, 6.06% market share of the first row3 injections, injection with pemequer disodium was included in the first batch of 4 plus 7 band quantity procurement, as the only evaluation of the variety of enterprises, Huiyu Pharmaceutical successfully won the bidBefore the collection, the Peimei Quser market is mainly occupied by Howson, Qilu and Lilly, with volume procurement to help "barefoot enterprises" Huiyu pharmaceutical sales rose rapidly, to seize market sharemeters net data show that in 2019 key urban public hospitals chemical drug terminals (samples covered Beijing, Harbin, Changchun, Shenyang, Tianjin, Shijiazhuang, Taiyuan, Guangzhou, Shenzhen, Zhengzhou, Chongqing, Wuhan, Changsha, Shanghai, Jinan, Hangzhou, Nanjing, Fuzhou, Chengdu Xi'an 20 cities, of which 9 are 4 and 7 pilot cities) injection with PeimeiQuse ii sodium manufacturers competition pattern, Huiyu Pharmaceutical ranked third (sales increased by 32509.46 percent year-on-year), second only to Haussen, QiluWith the advantage of exclusive winning bid, Huiyu Pharmaceutical's market share increased from 0.06% in 2018 to 19.87% in 2019In September 2019, the 4 plus 7 expansion collection, Huiyu Pharmaceuticals and Lilly selected, sales are expected to reach a new levelinjection with azastine evaluation enterprises including Huiyu Pharmaceuticals and Zhengda Tianqing, the big probability of being selected in the third batch of national collection, and dositsaysai injection suis currently only Huiyu Pharmaceutical exclusive evaluation, but there have been 4 pharmaceutical companies according to the generic 4 categories of production, 6 pharmaceutical companies submitted a consistent evaluation supplementary application, will be born a second evaluation enterpriseWith the continuous promotion of national band procurement, "barefoot enterprise" Huiyu Pharmaceutical may continue to benefit8 large injections in the trial, with Yangzijiang, Qilu and other exchanges
April 8, April 10, Sichuan Huiyu Pharmaceuticals to copy 4 categories of submitted hydrochloric acid Palonosjun injection, injection botozoli listing application to obtain CDE acceptance, so far the company has submitted 11 injection son-listed applications according to the new registration classification (3 have been approved)Of the 11 injections, 6 have been laid out in The Yangzi River, and Qilu, Zhengda tianqing and Hengrui are all laid out 5Table 2: Sichuan Huiyu Pharmaceutical's new registered classification of the products and the so-callednote: sales of less than 30 million symbols, representing the in the trial of the 8 injections, in addition to the hydrochloric acid Palonosjun injection until the vomit nausea, the remaining 7 injections All are anti-tumor drugs, yew alcohol injection, injection boronzomi annual sales are more than 1 billion yuan, in 2018 China's public medical institutions terminal anti-tumor drug product competition pattern, respectively, in 2.58%, 1.71% ranked 16th and 17th injection with tamoxide, injection with hydrochloric acid benzodiazepine has been evaluated by enterprises, Hengrui Medicine broke the blank situation of tempoamine injection form in the domestic market; Form 3: Huiyu Pharmaceuticalhas has reported and no enterprise evaluation of the varieties
no enterprise evaluation of the 6 injections, Plesafu injection has not been approved, the product by Sanofi's Kenzan Pharmaceutical research and development, in December 2008 was approved by the FDA listed, in December 2018 was approved to enter the domestic market Huiyu Pharmaceutical's exclusive declaration, is expected to be the first imitation of the review approved for listing Huiyu Pharmaceutical's Yewalcohol injection to the new registered classification, although there are Yangzijiang, Shanghai Chongno submitted the product consistency evaluation supplementary application, but Huiyu Pharmaceutical's products from abroad to report domestic and included in the priority review, from the declaration progress, Huiyu Pharmaceutical's first evaluation of the probability is still very large 6 injection bends overtaking, these three to be transferred to the domestic Huiyu Pharmaceuticals adhering to the vision of becoming an international pharmaceutical company, after many years of development, the international layout is effective, in 2014 became China's first through the British GMP certification of anti-tumor injection production enterprises ; At present, the company has 9 injections approved in the European Union countries, respectively, injection with benzodiazepine hydrochloride, dositasathan injection, hydrochloric acid polyjubalic injection, hydrochloric acid Ilitocon injection, othalichloroquine injection, injection with pemelic sodium, pyridine acid injection and hydrochloric acid table jubiting injection Table 4: Huiyu Pharmaceuticals incorporated/to be included in the priority review varieties note: With the of the proposed priority review, 6 of the 9 injections have been declared on the domestic market, of which 5 varieties (13 acceptance numbers) have been included in the priority review, 1 variety (2 acceptance numbers) is to be included in the priority review, included in the reasons for the same production line, has been listed in the European Union, the application for domestic listing of generic drugs, Dossitasai, Dossietasa, dossei, the same as the approval Table 5: Huiyu Pharmaceuticalhas has been listed in the European Union but not in the domestic production of varieties hydrochloric acid polyjubalic than star injection, hydrochloric acid table soft than star injection, celiac acid injection 3 varieties have been approved in the European Union, Huiyu Pharmaceuticals once submitted in the domestic listing application, the high probability into the priority review, to achieve a curved over-the-top Minet data show that in 2018, China's public medical institutions terminal dojobi star, table soft star, pyridine acid sales of 2.685 billion yuan, 1.037 billion yuan, 20.002 billion yuan, respectively source: Mi net database, the company's official website note: data statistics as of April 15, if there are omissions, welcome to point the finger! the original title: This Sichuan pharmaceutical company is strong! 3 large injections lead the list, 4 and 7 varieties of sales soared 325 times, 6 varieties of curved overtaking